
HeartFlow Inc (HTFL) Stock Forecast & Price Target
HeartFlow Inc (HTFL) Analyst Ratings
Bulls say
HeartFlow Inc. has reported robust growth in its FFR-CT volume, achieving approximately 48% growth worldwide, which significantly contributed to a strong financial quarter, with revenues reaching $46.3 million and surpassing projections. The company’s gross margins improved to 76.8%, reflecting an upward trend in profitability, while management noted healthy fundamentals driving core business growth, including increased adoption of coronary CT angiography and expanding account utilization. Additionally, the anticipated revenue from plaque analysis in 2026, along with a well-positioned forecast for continued mid-20s revenue growth, underscores a positive outlook for HeartFlow's operational future.
Bears say
HeartFlow Inc. has reported a series of significant net losses since its inception, totaling $95.7 million for FY23 and $96.4 million for FY24, with expectations of continuing substantial losses in the foreseeable future. The company faces a potential reimbursement risk due to reliance on third-party payors, which may adversely affect the widespread adoption of its Heartflow Platform, especially if coverage and adequate reimbursement are not secured. Additionally, despite the endorsement of its diagnostic pathway by ACC and AHA guidelines, the lack of widespread adoption by healthcare providers may hinder future revenue growth, as indicated by relatively flat revenue projections of approximately $46.3 million for Q4 2025.
This aggregate rating is based on analysts' research of HeartFlow Inc and is not a guaranteed prediction by Public.com or investment advice.
HeartFlow Inc (HTFL) Analyst Forecast & Price Prediction
Start investing in HeartFlow Inc (HTFL)
Order type
Buy in
Order amount
Est. shares
0 shares